All News
Filter News
Found 631 articles
-
Portola Pharmaceuticals, Inc. Initiates Phase II Clinical Program in Heart Attack Patients With Its Novel Antiplatelet Agent, PRT060128
12/4/2007
-
Sangamo BioSciences, Inc. Appoints H. Ward Wolff as Executive Vice President and Chief Financial Officer
12/3/2007
-
Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
10/3/2007
-
Portola Pharmaceuticals, Inc. $60 Million Financing to Advance Its Therapeutic Programs
8/28/2007
-
Horizon Therapeutics Completes $30 Million Equity Financing to Advance Pipeline of 'GI-Friendly' NSAIDs for Mild-to-Moderate Pain
7/23/2007
-
Portola Pharmaceuticals, Inc. Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7/10/2007
-
Portola Pharmaceuticals, Inc. Announces Positive Phase II EXPERT Results
7/2/2007
-
Portola Pharmaceuticals, Inc. (Jobs) Announces Completion of $70 Million Series C Financing
5/7/2007
-
Reliant Technologies, Inc. Secures $15 Million in Venture Funding
4/19/2007
-
Portola Pharmaceuticals, Inc. Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
4/4/2007
-
Portola Pharmaceuticals, Inc. Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
3/29/2007
-
SmoothShapes Inc. Announces $15 Million "Series B" Financing From Three Arch Partners
3/13/2007
-
Horizon Therapeutics Completes $21M In Equity Financing To Advance Pipeline Of "GI-Friendly" NSAIDs For Mild-to-Moderate Pain
1/4/2007
-
Stanford University Medical Center Release: Lincoln E. Moses, Pioneer In Biostatistics, Dies At 84
12/26/2006
-
Stanford University Medical Center Release: Lincoln E. Moses, Pioneer In Biostatistics, Dies At 84
12/22/2006
-
Portola Pharmaceuticals, Inc. Announces The Appointment Of William R. Ringo To Its Board Of Directors
12/13/2006
-
Portola Pharmaceuticals, Inc. Presents Data Associated With Its Novel Anticoagulation Assay At American Heart Association Scientific Sessions
11/16/2006
-
Portola Pharmaceuticals, Inc. Advances ADP Program: Initiates Phase I Trial With IV Formulation, Trials With Oral Formulation Ongoing
10/31/2006
-
Hercules And Portola Pharmaceuticals, Inc. Announce A $20 Million Financing Agreement
10/17/2006
-
Sunshine Heart Company Pty Limited Announces A$20 Million Institutional Capital Raising
9/6/2006